ZaBeCor Announces Formation of New Subsidiary
US-based biotechnology company ZaBeCor Pharmaceuticals has announced the formation of its new subsidiary Biothorpe Pharmaceuticals, a biotechnology company focused on the development of siRNA, antisense and other molecular technologies for the treatment of cancer.
Biothorpe’s intellectual property portfolio includes the therapeutic use of siRNA and other oligonucleotides directed at Syk kinase. Biothorpe intends to license its intellectual property for the treatment of three cancers – acute myelogenous leukemia, B-cell lymphoma and chronic lymphocytic leukemia.
Biothorpe’s intellectual property is said to be based upon research conducted at the University of Pennsylvania School of Medicine and focuses on applications of siRNA to the molecular protein Syk kinase.
Alan Schreiber, chairman and CEO of ZaBeCor and Biothorpe, said: “ZaBeCor will continue to focus on inflammatory disorders, particularly on developing our anti-inflammatory drug candidate Excellair, while Biothorpe builds upon the research of applying siRNA technology toward malignant cells in the blood and lymphatic system. Together, we can use our expertise in inflammation, oncology and hematology to help develop treatments to save lives.”